The Impact of Perimenopause on Mood and Cognition: A Review of Neuroendocrine Mechanisms and Treatment Strategies View PDF

The impact of perimenopause on mood and cognition has garnered significant scientific interest, primarily due to the profound neuroendocrine changes that occur during this transitional period [1-5]. The fluctuating levels of sex hormones, particularly estrogen and progesterone, are central to understanding the neurobiological mechanisms underlying mood disturbances and cognitive alterations in perimenopausal women [6-10]. One of the key neuroendocrine mechanisms involves the fluctuations of estrogen and progesterone during the menopausal transition [11-15]. As documented in recent reviews, these hormonal variations exert a profound influence on the central nervous system, affecting mood regulation and cognitive functions [16]. Estrogen, especially estradiol, plays a pivotal role in modulating neurotransmitter systems, including serotonergic, dopaminergic, and cholinergic pathways, which are integral to mood stabilization and cognitive processes [17, 18]. The decline in estrogen levels of post-menopause is associated with increased vulnerability to mood disorders such as depression and anxiety, highlighting the hormone’s neuroprotective and neuromodulatory roles [16].

Further elucidating these mechanisms, neuroendocrine changes during menopause include alterations in hypothalamic-pituitaryadrenal axis activity, which can influence stress responses and mood regulation [19-23]. The neuroendocrine system’s adaptation to declining ovarian hormones may contribute to the onset of mood disturbances, with hot flashes and sleep disruptions serving as both symptoms and potential mediators of mood and cognitive impairment [24, 25]. The neuroendocrine alterations are not only limited to hormonal fluctuations but also involve changes in receptor density and sensitivity within the brain, impacting neural plasticity and cognitive resilience [26]. The relationship between estrogen and cognitive function has been extensively studied, with evidence suggesting that estrogen exerts neuroprotective effects that support memory, attention, and executive functions. Estrogen’s modulation of synaptic plasticity and neurogenesis is believed to underpin these cognitive benefits. Consequently, the decline in estrogen during perimenopause correlates with reports of cognitive decline, including memory lapses and decreased processing speed [27]. Systematic reviews and metaanalyses have reinforced the notion that hormone therapy, particularly estrogen-based regimens, can mitigate some of these cognitive deficits, although results vary depending on timing, formulation, and individual factors [26].

In addition to cognitive effects, mood disturbances during perimenopause are closely linked to neuroendocrine dysregulation [28-32]. The fluctuations in estrogen and progesterone influence serotonergic pathways, which are critical in the pathophysiology of depression [33-37]. Estrogen’s ability to enhance serotonergic transmission and receptor sensitivity suggests that hormonal fluctuations can precipitate or exacerbate depressive symptoms [31]. Moreover, stress-related mechanisms, including dysregulation of the hypothalamic-pituitary-adrenal axis, further compound mood disturbances, indicating a complex interplay between neuroendocrine factors and psychological stressors [38].

Treatment strategies aimed at alleviating mood and cognitive symptoms during perimenopause often involve hormone therapy, which has shown promise in improving both domains [39-43]. Hormone therapy, typically involving estrogen with or without progestogen, has been demonstrated to improve mood stability and cognitive performance in menopausal women [27]. The neuroprotective effects of estrogen are thought to be mediated through multiple pathways, including antioxidant properties, modulation of neurotrophic factors, and enhancement of synaptic connectivity [17]. However, the efficacy of hormone therapy is influenced by factors such as timing of initiation, duration, and individual health status, with some studies indicating potential risks that necessitate careful consideration [44]. Beyond hormone therapy, non-pharmacological interventions such as cognitive behavioral therapy and stress management techniques have been explored to address mood and cognitive issues. These approaches aim to mitigate the impact of neuroendocrine dysregulation by reducing psychological stress, which can further disrupt ovarian function and exacerbate neuropsychiatric symptoms [38]. The integration of psychological and hormonal treatments may offer a comprehensive approach to managing perimenopausal mood and cognitive disturbances.

Overall, the neuroendocrine mechanisms underlying mood and cognitive changes during perimenopause are complex and multifaceted. Fluctuations in estrogen and progesterone levels significantly influence neurotransmitter systems, receptor sensitivities, and neural plasticity, thereby affecting mood regulation and cognitive functions. Hormone therapy remains a cornerstone of treatment, with evidence supporting its benefits in mitigating neuropsychiatric symptoms, although individual factors must be considered. Future research continues to explore the nuanced interactions between neuroendocrine changes and psychological factors, aiming to optimize therapeutic strategies for women navigating this transitional phase.